Biology Reference
In-Depth Information
long-term protective effects in sheep with reperfused myocardial infarction.
J Cardiovasc Pharmacol 2006, 47:736-741.
33. Kristensen J, Maeng M, Rehling M, Berg JS, Mortensen UM, Nielsen SS,
Nielsen TT: Lack of acute cardioprotective effect from preischaemic erythropoi-
etin administration in a porcine coronary occlusion model. Clin Physiol Funct
Imaging 2005, 25:305-310.
34. Prunier F, Pfister O, Hadri L, Liang L, Del Monte F, Liao R, Hajjar RJ: Delayed
erythropoietin therapy reduces post-MI cardiac remodeling only at a dose that
mobilizes endothelial progenitor cells. Am J Physiol Heart Circ Physiol 2007,
292:H522-529.
35. Chanseaume S, Azarnoush K, Maurel A, Bellamy V, Peyrard S, Bruneval P,
Hagege AA, Menasche P: Can erythropoietin improve skeletal myoblast en-
graftment in infarcted myocardium? Interact Cardiovasc Thorac Surg 2007,
6:293-297.
36. Lipsic E, Meer P, Voors AA, Westenbrink BD, de Boer HC, van Zonneveld AJ,
Schoemaker RG, van Gilst WH, Zijlstra F, van Veldhuisen DJ: A single bolus
of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute
myocardial infarction: a randomized feasibility and safety study. Cardiovasc
Drug her 2006, 20:135-141.
37. Jorgensen E, Bindslev L, Ripa RS, Kastrup J: Epo 'cytokine-doping' of heart
disease patients, will it work? Eur Heart J 2006, 27:1767-1768.
38. Westenbrink BD, Lipsic E, Meer P, Harst P, Oeseburg H, Du Marchie Sarvaas
GJ, Koster J, Voors AA, van Veldhuisen DJ, van Gilst WH, Schoemaker RG:
Erythropoietin improves cardiac function through endothelial progenitor cell
and vascular endothelial growth factor mediated neovascularization. Eur Heart
J 2007, 28:2018-2027.
39. Ferrario M, Massa M, Rosti V, Campanelli R, Ferlini M, Marinoni B, De Ferrari
GM, Meli V, De Amici M, Repetto A, Verri A, Bramucci E, Tavazzi L: Early
haemoglobin-independent increase of plasma erythropoietin levels in patients
with acute myocardial infarction. Eur Heart J 2007, 28:1805-1813.
Search WWH ::
Custom Search